In this episode, Ed is joined by Ben Taylor, Chief Financial Officer and President of Recursion UK, to discuss how AI is reshaping drug discovery, biotech, and the future of medicine.<br><br>Ben explains how Recursion uses AI, lab automation, biological data, and machine learning to improve the way new medicines are discovered and developed. They explore why drug discovery has such a high failure rate, how AI can open up new areas of biology, and what this could mean for healthcare over the next decade.

How Recursion Is Using AI to Rethink Drug Discovery

Opto Sessions – Invest in the Next Big Idea

Hello everyone, we've got Ben Taylor on the show today, Chief Financial Officer and President of Recursion UK, bringing more than two decades of healthcare, finance and biopharma transaction experience, including senior roles at Accenture, Goldman Sachs and Barclays. At Recursion he helps lead the company's financial strategy and UK presence as it advances its technology enabled drug discovery platform. How are you doing today Ben? Great, thanks for having me on.

Where are you calling from? Are you based in the UK? I am, yeah, well I technically live in London, although I'm on the road so much sometimes it feels like this is just where I change the clothes in my suitcase. The company's based out of US, is that right? So we've got a good mix actually. So the Legacy Recursion headquarters was in Salt Lake City, the Legacy Accenture was in the UK.

And so we have large operations in both and then we also have some smaller offices around including New York, which is where our CEO is. Okay, okay. And just for everyone who doesn't know the company, I thought we'd just give a brief overview of what Recursion is. So if you could do that, that'd be great.

Yeah, of course. I'll keep you really tight. Basically, we use AI and lab automation to improve the quality and efficiency of making novel medicines and thereby improving the probability of success of really getting that idea into a final drug that can be used with patients. Mm-hmm. And I think I'm right in saying you're coming across from Accenture in a relatively recent merger. Yes.

How Recursion Is Using AI to Rethink Drug Discovery

Read the full transcript

The candid version is on a podcast,
not the earnings call.

How Recursion Is Using AI to Rethink Drug Discovery

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.